No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock was $29.62 as of Oct 6, 2026, 11:25 AM EDT, down 3.17% from the previous close.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders.
Biotechnology · Cambridge, MA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.80
vs Estimate
$-0.73
Revenue
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1COAG | $1.38B | $29.62 | -3.17% | N/A | N/A | N/A | N/A |
| 2PNTG | $1.41B | $40.56 | +0.65% | +55.51% | +8.88% | N/A | vs COAG |
| 3OMER | $1.35B | $18.72 | -0.95% | +309.88% | +21.70% | +6.50% | vs COAG |
| 4INBX | $1.42B | $96.54 | +2.09% | +164.01% | +27.64% | N/A | vs COAG |
| 5KLRA | $1.43B | $11.04 | +1.85% | N/A | N/A | N/A | vs COAG |
| 6ANAB | $1.44B | $48.64 | -1.14% | +137.50% | +21.54% | N/A | vs COAG |
forward FY estimate
N/A
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$61.20
+106.6% upside
Low
$58.00
Current
$29.62
High
$65.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.55 | $-0.51 | $-0.46 | 3 |
| Quarter ending Dec 2026 | $-0.58 | $-0.57 | $-0.55 | 3 |
| Quarter ending Mar 2027 | $-0.54 | $-0.54 | $-0.54 | 1 |
| Quarter ending Jun 2027 | $-0.61 | $-0.61 | $-0.61 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.20 | $-3.10 | $-2.99 | 3 |
| FY 2027 | $-2.70 | $-2.54 | $-2.37 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
